Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States

Arvind Dasari, Chan Shen, Daniel M. Halperin et al. · JAMA Oncology · 2017 · 3.5K citations · Full text

Medicine, Oncology, Surgery +17

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

James C. Yao, Manisha H. Shah, Tetsuhide Ito et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text

Medicine, Oncology, Surgery +12

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · New England Journal of Medicine · 2011 · 2.5K citations

Medicine, Oncology, Pharmacology +11

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · Journal of Clinical Oncology · 2009 · 2.5K citations

Medicine, Oncology, Pharmacotherapy +17